Published Mar 26, 2019

Abcuro announces pre-clinical data on new immuno-oncology target

First in vivo validation of KLRG1 as a new cancer immunotherapy target

Related or similar articles

May 17, 2024

Streamlining Procurement: Labshares Partners with Labviva for Enhanced Access and Efficiency

In the fast-paced world of biotech innovation, easy access to crucial resources is vital for research success. That's why Labshares is excited to share news of our partnership with Labviva, a top procurement platform reshaping how scientists obtain l

June 28, 2024

Incubators vs. Shared Laboratories: Finding the Best Fit for Your Biotech Startup

June 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.